Array
(
    [id] => chatcmpl-AipYgBQO1jbklNRK3FNQIyXn5tL0G
    [object] => chat.completion
    [created] => 1735247986
    [model] => gpt-4o-mini-2024-07-18
    [choices] => Array
        (
            [0] => Array
                (
                    [index] => 0
                    [message] => Array
                        (
                            [role] => assistant
                            [content] => - OSI-7904L is a liposomal version of the thymidylate synthase inhibitor OSI-7904, developed to improve its effectiveness and ease of use in cancer treatment. *!  
- In studies on mice with human colon cancer, OSI-7904L showed better tumor-fighting results and required less frequent dosing compared to OSI-7904 and 5-fluorouracil. *!  
- While OSI-7904L increased the drug's potency and exposure in tumors, it also presented greater toxicity, particularly affecting the intestines, bone marrow, and thymus, indicating a trade-off between efficacy and safety. *!
                            [refusal] => 
                        )

                    [logprobs] => 
                    [finish_reason] => stop
                )

        )

    [usage] => Array
        (
            [prompt_tokens] => 485
            [completion_tokens] => 139
            [total_tokens] => 624
            [prompt_tokens_details] => Array
                (
                    [cached_tokens] => 0
                    [audio_tokens] => 0
                )

            [completion_tokens_details] => Array
                (
                    [reasoning_tokens] => 0
                    [audio_tokens] => 0
                    [accepted_prediction_tokens] => 0
                    [rejected_prediction_tokens] => 0
                )

        )

    [system_fingerprint] => fp_0aa8d3e20b
)